Journal
ANALYTICAL CHEMISTRY
Volume 82, Issue 23, Pages 9711-9718Publisher
AMER CHEMICAL SOC
DOI: 10.1021/ac101804s
Keywords
-
Categories
Funding
- NIH/NIAID [5K25AI060884]
- NIH/NIDA [T32DA007232, F31DA025398]
Ask authors/readers for more resources
In this work, we evaluate for the first time the performance of a label free porous silicon (PSI) immunosensor assay in a blind clinical study designed to screen authentic patient urine specimens for a broad range of opiates The PSI opiate immunosensor achieved 96% concordance with liquid chromatography-mass spectrometry/tandem mass spectrometry (LC-MS/MS) results on samples that underwent standard opiate testing (n = 50) In addition, successful detection of a commonly abused opiate, oxycodone, resulted in 100% qualitative agreement between the PSi opiate sensor and LC-MS/MS In contrast, a commercial broad opiate immunoassay technique (CEDIA) achieved 65% qualitative concordance with LCMS/MS Evaluation of important performance attributes including precision, accuracy, and recovery was completed on blank urine specimens spiked with test analytes Variability of morphine detection as a model opiate target was <9% both within run and between day at and above the cutoff limit of 300 ng mL(-1) This study validates the analytical screening capability of label-free PSI opiate immunosensors in authentic patient samples and is the first semiquantitative demonstration of the technology's successful clinical use These results motivate future development of label-free PSI technology to reduce complexity and cost of diagnostic testing particularly in a point-of care setting
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available